LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Strona główna・Stock List・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Closed

Sector Healthcare

1.43 -4.67

Buy Sell

Overview

Share price change

24h

Current

Min

1.41

Max

1.5

Key metrics
By Trading Economics
Income	15M 614K
Sales	14M 56M
P/E Sector Avg	26.504 79.786
EPS	-0.08
Profit margin	1.093
Employees	167
EBITDA	14M 11M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+204.05 upside

Dividends
By Dow Jones
Next Earnings	23 sie 2024

Market Stats
By TradingEconomics
Market Cap	10M 322M
Previous open	6.1
Previous close	1.43

News Sentiment

By Acuity

50%

123 / 369 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

1.46 / 1.47 Support & Resistance

Akebia Therapeutics Inc Chart

Related News

28 mar 2024, 10:30 UTC

Major Market Movers

Akebia Shares Rally Premarket After FDA Approves Vafseo

Peer Comparison

Price change

Akebia Therapeutics Inc Forecast

Price Target

By TipRanks

204.05% upside

12 Months Forecast

Average 4.5 USD 204.05%

High 5 USD

Low 4 USD

Based on 2 Wall Street analysts offering 12 month price targets forAkebia Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Akebia Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.46 / 1.47Support & Resistance

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

123 / 369 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.